Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma

Biologics: Targets and Therapy

Volumn 2, Issue 4, 2008, Pages 601-609

  Porta, Camillo ^a   Paglino, Chiara ^a   Mutti, Luciano ^b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b Local Health Authority   (Italy)

Author keywords

Antitumor activity; Doxorubicin; Mesothelioma; Ranpirnase; Ribonucleases

Indexed keywords

EID: 74649086633     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/btt.s2383     Document Type: Review

References (56)

1. Ardelt W, Mikulski SM, Shogen K. 1991. Amino acid sequence of an anti-tumor protein from Rana pipiens oocytes and early embryos. Homology to pancreatic ribonucleases. J Biol Chem, 266:245-51.
2. Ardelt B, Juan G, Burfeind P, et al. 2007. Onconase, an anti-tumor ribonuclease, suppresses intracellular oxidative stress. Int J Oncol, 31:663-9.
3. Arnold U, Ulbrich-Hofmann R. 2006. Natural and engineered ribonucleases as potential cancer therapeutics. Biotechnol Lett, 28:1615-22.
4. Benito A, Ribó M, Vilanova M. 2005. On the track of antitumour ribonucleases. Mol Biosyst, 1:294-302.
5. Boix E, Wu Y, Vasandani VM, et al. 1996. Role of the N terminus in RNase A homologues. Differences in catalytic activity, ribonuclease inhibitor interaction and cytotoxicity. J Mol Biol, 257:992-1007.
6. Bruserud O. 2007. Introduction: RNA and the treatment of human cancer. Curr Pharm Biotechnol, 8:318-9.
7. Carbone M, Emri S, Dogan AU, et al. 2007. A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nat Rev Cancer, 7:147-54.
8. Chun H, Costanzi J, Mittelman A, et al. 1995, Phase I/II trial of onconase (ONC) plus tamoxifen (TMX) in patients (pts) with advanced pancreatic carcinoma (APC) [abstract]. Proc Am Soc Clin Oncol, 517.
9. Costanzi J, Sidransky D, Navon A, et al. 2005. Ribonucleases as a novel pro-apoptotic anticancer strategy: review of the pre-clinical and clinical data for ranpirnase. Cancer Invest, 23:643-50.
10. D'Alessio G, Di Donato A, Mazzarella L, et al. 1997. Seminal ribonuclease: the importance of diversity. In: D'Alessio G, Riordan JF (eds.) Ribonucleases: structures and functions. New York, NY, U S A: Academic Press. pp. 383-423.
11. Darzynkiewicz Z, Carter SP, Mikulski SM, et al. 1988. Cytostatic and cytotoxic effect of Pannon (P-30 protein), a novel anticancer agent. Cell Tissue Kinet, 21:169-82.
12. Deptala A, Halicka HD, Ardelt B, et al. 1998. Potentiation of tumor necrosis factor-induced apoptosis by Onconase. Int J Oncol, 13:11-6.
13. Fennell DA, Gaudino G, O'Byrne KJ, et al. 2008. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Cancer, 5:136-47.
14. Halicka DH, Juan G, Ardelt B, et al. 1996. Induction of differentation and apoptosis of U937 and HL-60 cells by Onconase: potentiation by inhibitors of protein kinases. Proc Am Soc Clin Oncol, 15:18 (abs.).
15. Herndon JE, Green MR, Chahinian AP, et al. 1998. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest, 113:723-31.
16. Hofsteenge J. 1997. Ribonuclease inhibitor. In: D'Alessio G, Riordan JF (eds.). Ribonucleases: structures and functions. New York, NY, USA: Academic Press. pp. 621-58.
17. Iordanov MS, Ryabinina OP, Wong J et al. 2000. Molecular determinants of apoptosis induced by the cytotoxic ribonuclease onconase: evidence for cytotoxic mechanisms different from inhibition of protein synthesis. Cancer Res, 60:1983-94.
18. Iordanov MS, Wong J, Newton Dl, et al. 2000. Differential requirements for the stress-activated protein kinase/c-Jun NH(2) terminal kinase in RNA damage-induced apoptosis in primary and in immortalized fibroblasts. Mol Cell Biol Res Commun, 4:122-8.
19. Irie M, Nitta K, Nonaka T. 1998. Biochemistry of frog ribonucleases. Cell Mol Life Sci, 54:775-84.
20. KIP and decreased pRB phosphorylation. Leukemia, 12:1241-8.
21. Kim DH, Kim EJ, Kalota A, et al. 2007. Possibile mechanisms of improved radiation response by cytotoxic RNase, Onconase, on A549 human lung cancer xenografts of nude mice. Adv Exp Med Biol, 599:53-9.
22. Korn EL, Arbuck SG, Pluda JM, et al. 2001. Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol, 19:265-72.
23. Ledoux L, Balthus E. 1954. Action de la ribonucléase sur les cellules du carcinoma d'Erlich. Experientia, 10:500-1.
24. Ledoux L. 1955. Action of ribonuclease on two solid tumours in vivo. Nature, 176:36-7.
25. Lee I, Lee YH, Mikulski SM, et al. 2000. Enhanced cellular radiation sensitivity of androgen-independent human prostate tumor cells by Onconase. Anticancer Res, 20:1037-40.
26. Lee I, Lee YM, Mikulski SM, et al. 2000. Tumoricidal effects of Onconase on various tumors. J Surg Oncol, 73:164-71.
27. Lee I, Lee YM, Mikulski SM, et al. 2003. Effect of Onconase LLtamoxifen on ASPC-1 human pancreatic tumors in nude mice. Adv Exp Med Biol, 530:187-96.
28. Lee I, Kalota A, Gerwitz AM, et al. 2007. Antitumor efficacy of the cytotoxic RNase, Ranpirnase, on A549 human lung cancer xenografts of nude mice. Anticancer Res, 27:299-308.
29. Lee I, Kim DH, Sunar U, et al. 2007. The therapeutic mechanism of ranpirnase-induced enhancement of radiation response on A549 human lung cancer. In Vivo, 21:721-8.
30. Lee I, Shogen K. 2008. Mechanism of enhanced tumoricidal efficacy of multiple small dosages of Ranpirnase, the novel cytotoxic ribonuclease, on lung cancer. Cancer Chemother Pharmacol, 62:337-46.
31. Lee JE, Raines RT. 2008. Ribonucleases as novel chemotherapeutics: the ranpirnase example. BioDrugs, 22:53-8.
32. Leland PA, Schultz LW, Kim BM, et al. 1998. Ribonuclease A variants with potent cytotoxic activity. Proc Natl Acad Sci U S A, 95:10407-12.
33. Leland PA, Raines RT. 2001. Cancer chemotherapy-ribonucleases to the rescue. Chem Biol, 8:405-13.
34. Michaelis M, Cinatl J, Anand P, et al. 2007. Onconase induces caspaseindependant cell death in chemoresistant neurobastoma cells. Cancer Lett, 250:107-16.
35. Mikulski SM, Ardelt W, Shogen K, et al. 1990. Striking increase of survival of mice bearing M109 Madison carcinoma treated with a novel protein from amphibian embryos. J Natl Cancer Inst, 82:151-3.
36. Mikulski SM, Viera A, Ardelt W, et al. 1990. Tamoxifen and trifluoroperazine (Stelazine) potenziate cytostatic/cytotoxic effects of P-30 protein, a novel protein possessing anti-tumour activity. Cell Tissue Kinet, 23:237-46.
37. Mikulski SM, Viera A, Shogen K. 1992. In vitro synergism between a novel amphibian oocytic ribonuclease (Onconase) and tamoxifen, lovastatin and cisplatin, in human OVCAR-3 ovarian carcinoma cell line. Int J Oncol, 1:77-85.
38. Mikulski SM, Grossman AM, Carter PW, et al. 1993. Phase I human clinical trial of Onconase (P-30 protein) administered intravenously on a weekly schedule in cancer patients with solid tumors. Int J Oncol, 3:57-64.
39. Mikulski SM, Chun HG, Mittelman A, et al. 1995. Relationship between response rate and median survival in patients with advanced non-small cell lung cancer: comparison of-Onconase® with other anticancer agents. Int J Oncol, 6:889-97.
40. Mikulski SM, Newton DL, Wiltrout RH, et al. 1999. Onconase and doxorubicin synergy in prolonging survival of MDA-MB-231 human breast cancer-bearing nude mice [abstract]. Proc Am Assoc Cancer Res, 40:491(abs. 3246).
41. Mikulski SM, Costanzi JJ, Vogelzang NJ, et al. 2002. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol, 20:274-81.
42. Mosimann SC, Johns KL, Ardelt W, et al. 1992. Comparative molecular modeling and crystallization of P-30 protein: a novel antitumor protein of Rana pipiens oocytes and early embryos. Proteins, 14:392-400.
43. Newton DL, Hansen HJ, Mikulski SM, et al. 2001. Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma. Blood, 97:528-35.
44. Pavlakis N, Vogelzang NJ. 2006. Ranpirnase-an antitumour ribonuclease: its potential role in malignant mesothelioma. Expert Opin Biol Ther, 6:391-9.
45. Peto J, Recarli A, La Vecchia C, et al. 1999. The European mesothelioma epidemic. Br J Cancer, 79:666-72.
46. Puccio C, Mittelman A, Chun H et al. 1996. A new anticancer RNase (Onconase): clinical trial in patients (pts) with breast cancer (BC) [abstract]. Proc Am Soc Clin Oncol, 242.
47. Ramos-Nino ME, Vianale G, Sabo-Attwood T, et al. 2005. Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase. Mol Cancer Ther, 4:835-42.
48. Riordan JF. Structure and function of angiogenin. 1997. In: D'Alessio G, Riordan JF (eds.). Ribonucleases: structures and functions. New York, NY, U S A: Academic Press. pp. 445-89.
49. Rybak SM, Pearson JW, Foglerwe, et al. 1996. Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with onconase, an antitumor ribonuclease. J Natl Cancer Inst, 88:747-53.
50. Shacter E, Williams JA, Hinson RM, et al. 2000. Oxidative stress interferes with cancer chemotherapy: inhibition of lymphoma cell apoptosis and phagocytosis. Blood, 96:307-13.
51. Vasandani VM, Wu YN, Mikulski SM, et al. 1996. Molecular determinants in the plasma clearance and tissue distribution of ribonucleases of the ribonuclease A superfamily. Cancer Res, 56:4180-6.
52. Vasandani VM, Burris JA, Sung C. 1999. Reversible nephrotoxicity of onconase and effect of lysine pH on renal onconase uptake. Cancer Chemother Pharmacol, 44:164-9.
53. Vogelzang N, Taub R, Shin D, et al. 2000. Phase III randomized trial of onconase (ONC) versus doxorubicin (DOX) in patients (Pts) with unresectable malignant mesothelioma (UMM): analysis of survival [abstract]. Proc Am Soc Clin Oncol, 2274.
54. Vogelzang NJ, Aklilu M, Stadler WM, et al. 2001. A Phase II trial of weekly intravenous ranpirnase (Onconase), a novel ribonuclease in patients with metastatic kidney cancer. Invest New Drugs, 3:255-60.
55. Vogelzang NJ, Porta C, Mutti L. 2005. New agents in the management of advanced mesothelioma. Semin Oncol, 32:336-50.
56. Wu Y, Mikulski SM, Ardelt W, et al. 1993. A cytotoxic ribonuclease. Study of the mechanism of onconase cytotoxicity. J Biol Chem, 268:10686-93.